HURA Key Statistics, Chart & Performance
The current stock price of HURA is 1.87 USD. In the past month the price decreased by -28.74%. In the past year, price decreased by -72.9%.
HURA Latest News, Press Relases and Analysis
HURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.38B | ||
| AMGN | AMGEN INC | 15.74 | 185.37B | ||
| GILD | GILEAD SCIENCES INC | 15.2 | 154.42B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.46 | 116.57B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.13 | 76.29B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 932.08 | 62.80B | ||
| INSM | INSMED INC | N/A | 44.01B | ||
| NTRA | NATERA INC | N/A | 32.68B | ||
| BIIB | BIOGEN INC | 10.85 | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.15 | 20.62B | ||
| INCY | INCYTE CORP | 15.73 | 19.83B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.23B |
Related stock screener links
About HURA
Company Profile
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
Company Info
TUHURA BIOSCIENCES INC
10500 University Center Dr., Suite 110
Tampa FLORIDA US
Employees: 19
Phone: 18138756600
TUHURA BIOSCIENCES INC / HURA FAQ
What does HURA do?
TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The company is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. The company is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.
What is the stock price of TUHURA BIOSCIENCES INC today?
The current stock price of HURA is 1.87 USD. The price increased by 3.31% in the last trading session.
What is the dividend status of TUHURA BIOSCIENCES INC?
HURA does not pay a dividend.
What is the ChartMill technical and fundamental rating of HURA stock?
HURA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of TUHURA BIOSCIENCES INC (HURA) based on its PE ratio?
TUHURA BIOSCIENCES INC (HURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.49).
How many employees does TUHURA BIOSCIENCES INC have?
TUHURA BIOSCIENCES INC (HURA) currently has 19 employees.
What is TUHURA BIOSCIENCES INC worth?
TUHURA BIOSCIENCES INC (HURA) has a market capitalization of 95.86M USD. This makes HURA a Micro Cap stock.
HURA Technical Analysis
HURA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to HURA. HURA has a bad profitability rating. Also its financial health evaluation is rather negative.
HURA Financial Highlights
Over the last trailing twelve months HURA reported a non-GAAP Earnings per Share(EPS) of -9.49. The EPS increased by 62.78% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -112.19% | ||
| ROE | -199.71% | ||
| Debt/Equity | 0.02 |
HURA Forecast & Estimates
9 analysts have analysed HURA and the average price target is 9.75 USD. This implies a price increase of 421.59% is expected in the next year compared to the current price of 1.87.